Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an update.
On December 8, 2025, Ascentage Pharma presented updated data on Olverembatinib at the ASH Annual Meeting, showcasing its potential as a second-line treatment for chronic myeloid leukemia in chronic-phase (CML-CP). The data revealed a 76.7% complete cytogenetic response rate in patients who failed second-generation TKI first-line therapy, with responses deepening over time. The study highlighted Olverembatinib’s efficacy and safety, supporting its advancement to earlier treatment lines and broader clinical application. The drug is already approved in China for certain CML indications and is being evaluated in global Phase III studies for various conditions. This development reaffirms Ascentage Pharma’s commitment to addressing unmet medical needs and strengthens its position in the global hematology field.
The most recent analyst rating on (AAPG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The overall stock score reflects significant financial challenges, including high debt levels and negative profitability, which are the most impactful factors. The technical analysis indicates weak momentum, and the valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall score.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage, integrated biopharmaceutical company focused on the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company is known for its innovative pipeline, including drugs like Olverembatinib, Lisaftoclax, and APG-5918, and has a market presence in China and plans for global expansion.
Average Trading Volume: 7,201
Technical Sentiment Signal: Hold
Current Market Cap: $3.03B
See more data about AAPG stock on TipRanks’ Stock Analysis page.